Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABBV-151 + Budigalimab |
Synonyms | |
Therapy Description |
Limited information is currently available on ABBV-151 (Feb, 2019). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-151 | ARGX-115|ABBV151|ABBV 151|ARGX 115|ARGX-115|ARGX115|Livmoniplimab | ABBV-151 is a monoclonal antibody that targets the glycoprotein A repetitions predominant (GARP)-transforming growth factor beta 1 (TGFbeta1) complex, which prevents release of active TGF-beta1, potentially leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). | ||
Budigalimab | ABBV181|ABBV 181|ABBV-181 | Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 101 | Budigalimab is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32770720). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | CAN | BEL | 6 |